scholarly journals Toxicologic Assessment of a Commercial Decolorized Whole Leaf Aloe Vera Juice, Lily of the Desert Filtered Whole Leaf Juice with Aloesorb

2013 ◽  
Vol 2013 ◽  
pp. 1-12 ◽  
Author(s):  
Inder Sehgal ◽  
Wallace D. Winters ◽  
Michael Scott ◽  
Andrew David ◽  
Glenn Gillis ◽  
...  

Aloe vera, a common ingredient in cosmetics, is increasingly being consumed as a beverage supplement. Although consumer interest in aloe likely stems from its association with several health benefits, a concern has also been raised by a National Toxicology Program Report that a nondecolorized whole leaf aloe vera extract taken internally by rats was associated with intestinal mucosal hyperplasia and ultimately malignancy. We tested a decolorized whole leaf (DCWL) aloe vera, treated with activated charcoal to remove the latex portion of the plant, for genotoxicity in bacteria, acute/subacute toxicity in B6C3F1 mice, and subchronic toxicity in F344 rats. We found this DCWL aloe vera juice to be nongenotoxic in histidine reversion and DNA repair assays. Following acute administration, mice exhibited no adverse signs at 3- or 14-day evaluation periods. When fed to male and female F344 rats over 13 weeks, DCWL aloe led to no toxicity as assessed by behavior, stools, weight gain, feed consumption, organ weights, and hematologic or clinical chemistry profiles. These rats had intestinal mucosal morphologies—examined grossly and microscopically—that were similar to controls. Our studies show that oral administration of this DCWL aloe juice has a different toxicology profile than that of the untreated aloe juice at exposures up to 13 weeks.

2020 ◽  
Vol 15 (7) ◽  
pp. 1934578X2094165
Author(s):  
Hyoung-Yun Han ◽  
Kang-Hyun Han ◽  
Jun-Ho Ahn ◽  
Se-Myo Park ◽  
Soojin Kim ◽  
...  

Phytolacca americana L. is traditionally used in Korea, Japan, and China as a diuretic, antibacterial, antiviral, anticancer, and anti-inflammatory agent, and also in the treatment of hepatitis B, psoriasis, edema, and rheumatism. In this study, we evaluated the subchronic toxicity of an aqueous extract of P. americana (PAAE) in male and female F344 rats. The rats were orally administered PAAE (0, 500, 1000, and 2000 mg/kg body weight) once daily for 13 weeks. Mortality rate, body weight, food consumption, and organ weights were measured and assessed. Additionally, ophthalmological, hematological, and histopathological parameters were evaluated. Urinalysis and necropsy were also performed. The clinical chemistry values for potassium in the treated female groups (500, 1000, and 2000 mg/kg/ body weight/day) were higher than those in the control. Further, the relative weights of the kidneys in the treated female groups (1000 and 2000 mg/kg/ body weight/day) were higher than those in the control. However, these changes were not consistent in either sex, and no abnormalities were found in the corresponding pathological findings. Thus the results showed no adverse effects in all the parameters assessed. The findings show that after 13 weeks of treatment, the “no-observed-adverse-effect level” of PAAE is 2000 mg/kg body weight in both male and female F344 rats under the experimental conditions applied. Although treatment-related adverse effects were not seen, potassium-level changes in the blood should be examined to establish the safety profile of PAAE after long-term treatment.


1996 ◽  
Vol 29 (2) ◽  
pp. 185-193
Author(s):  
DAVID L. GREENMAN ◽  
ROBERT L. MORRISSEY ◽  
WILLIAM BLAKEMORE ◽  
JAMES CROWELL ◽  
PAUL SIITONEN ◽  
...  

2004 ◽  
Vol 207 (1) ◽  
pp. 119-125 ◽  
Author(s):  
Ming W Chou ◽  
Jian Yan ◽  
Jasyl Nichols ◽  
Qingsu Xia ◽  
Frederick A Beland ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Chongshan Dai ◽  
Xilong Xiao ◽  
Yonglei Yuan ◽  
Gaurav Sharma ◽  
Shusheng Tang

Fulvic acid (FA), a humic substance, has several nutraceutical properties, including anti-inflammation, antimicrobial, and immune regulation abilities. However, systematic safety assessment remains insufficient. In the present study, a battery of toxicological studies was conducted per internationally accepted standards to investigate the genotoxicity and repeated-dose oral toxicity of FA. Sprague-Dawley (SD) rats or ICR mice were used. Compared to the control group, there were no significant changes (all p > 0.05 ) in all FA treatment groups in the bacterial reverse mutation test, in vitro mammalian chromosome aberration test, in vivo sperm shape abnormality assay, and in vivo mouse micronucleus assay. The acute toxicity test showed that no mortality or toxic effect was observed following oral administration of the maximum dose of 5,000 mg/kg BW/day to mice or rats. A 60-day subchronic study was conducted at 0 (control), 200, 1,000, and 5,000 mg/kg/day. Compared to the control group, there were no significant changes (all p > 0.05 ) in the body weights, feed consumption, clinical signs, hematology, clinical chemistry, organ weights, or histopathology examinations. In conclusion, the no-observed-adverse-effect-level (NOAEL) of FA supplementation from the 60-day study was determined to be 5,000 mg/kg body weight/day, the highest dose tested. Our findings suggest that the oral administration of FA may have higher safety.


Sign in / Sign up

Export Citation Format

Share Document